open access

Vol 65, No 2 (2014)
Original papers
Published online: 2014-05-06
Submitted: 2014-05-06
Accepted: 2014-05-06
Get Citation

The effect of calpain-10 gene polymorphism on the development of type 2 diabetes mellitus in a Turkish population

Emre Arslan, Leyla Acik, Gulsah Gunaltili, Goksun Ayvaz, Alev E. Altinova, Metin Arslan
DOI: 10.5603/EP.2014.0013
·
Endokrynologia Polska 2014;65(2):90-95.

open access

Vol 65, No 2 (2014)
Original papers
Published online: 2014-05-06
Submitted: 2014-05-06
Accepted: 2014-05-06

Abstract

Introduction: The variations in the Calpain-10 gene have been suggested to be related to susceptibility to type 2 diabetes mellitus (T2DM) in different populations. In this study, we investigated the relationship between single nucleotide polymorphism (SNP)-19, -44 and -63 in the Calpain-10 gene and the development of T2DM in a Turkish population.

Material and methods: A total of 211 subjects were recruited: 118 patients with a diagnosis of T2DM and 93 unrelated healthy subjects.

Results: There were no significant differences in the genotype and allele distribution of SNPs studied between the patients with T2DM and controls (p > 0.05), whereas the frequencies of 121 haplotype and 122/121 haplotype combination were found to be higher in patients with T2DM than in controls (p < 0.05). No association was observed between the variations in the Calpain-10 gene and glycaemic control and lipid parameters (p > 0.05). The SNP-19 insertion/insertion was significantly related to increased body mass index (BMI) in male diabetic patients (p < 0.05).

Conclusions: The present study indicates that 121 haplotype and 122/121 haplotype combination of SNP-19, -44 and -63 in the Calpain-10 gene are associated with the development of T2DM in Turkish patients. (Endokrynol Pol 2014; 65 (2): 90–95)

Abstract

Introduction: The variations in the Calpain-10 gene have been suggested to be related to susceptibility to type 2 diabetes mellitus (T2DM) in different populations. In this study, we investigated the relationship between single nucleotide polymorphism (SNP)-19, -44 and -63 in the Calpain-10 gene and the development of T2DM in a Turkish population.

Material and methods: A total of 211 subjects were recruited: 118 patients with a diagnosis of T2DM and 93 unrelated healthy subjects.

Results: There were no significant differences in the genotype and allele distribution of SNPs studied between the patients with T2DM and controls (p > 0.05), whereas the frequencies of 121 haplotype and 122/121 haplotype combination were found to be higher in patients with T2DM than in controls (p < 0.05). No association was observed between the variations in the Calpain-10 gene and glycaemic control and lipid parameters (p > 0.05). The SNP-19 insertion/insertion was significantly related to increased body mass index (BMI) in male diabetic patients (p < 0.05).

Conclusions: The present study indicates that 121 haplotype and 122/121 haplotype combination of SNP-19, -44 and -63 in the Calpain-10 gene are associated with the development of T2DM in Turkish patients. (Endokrynol Pol 2014; 65 (2): 90–95)

Full Text:

View HTML
Get Citation

Keywords

Calpain-10; haplotype; SNP; type 2 diabetes

About this article
Title

The effect of calpain-10 gene polymorphism on the development of type 2 diabetes mellitus in a Turkish population

Journal

Endokrynologia Polska

Issue

Vol 65, No 2 (2014)

Pages

90-95

Published online

2014-05-06

DOI

10.5603/EP.2014.0013

Bibliographic record

Endokrynologia Polska 2014;65(2):90-95.

Keywords

Calpain-10
haplotype
SNP
type 2 diabetes

Authors

Emre Arslan
Leyla Acik
Gulsah Gunaltili
Goksun Ayvaz
Alev E. Altinova
Metin Arslan

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl